Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile
Autore:
Martenyi, F; Dossenbach, M; Mraz, K; Metcalfe, S;
Indirizzi:
Eli Lilly & Co, Reg Med Ctr, A-1030 Vienna, Austria Eli Lilly & Co Vienna Austria A-1030 Reg Med Ctr, A-1030 Vienna, Austria
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
fascicolo: 3, volume: 11, anno: 2001,
pagine: 227 - 232
SICI:
0924-977X(200106)11:3<227:GDITEO>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
MENSTRUAL-CYCLE; HUMAN BRAIN; SEX; MENOPAUSE; THERAPY; AGE;
Keywords:
major depression; fluoxetine; maprotiline; gender differences;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Martenyi, F Eli Lilly & Co, Reg Med Ctr, Barichgasse 40-42, A-1030 Vienna,Austria Eli Lilly & Co Barichgasse 40-42 Vienna Austria A-1030 ustria
Citazione:
F. Martenyi et al., "Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile", EUR NEUROPS, 11(3), 2001, pp. 227-232

Abstract

Background: Depression has emerged as a contrastive area of gender differences in psychiatry, as epidemiological data has consistently shown depression is twice as common in women as men. The pharmacodynamic effect of antidepressants may also show gender differences, as suggested by reports of better response of young women to non-tricyclic antidepressants. Methods: The antidepressive effect of an SSRI (fluoxetine) and a tetracyclic antidepressant with selective norepinephrine reuptake inhibitory effect (maprotiline) was compared in a 6-week, double-blind trial of 105 depressed patients. Results: No significant difference was observed in the change of HAMD17 total score from baseline to week 6 between fluoxetine- and maprotiline-treated patients. A significant difference was observed in females (fluoxetine, -17.8; maprotiline, -13.9; P=0.017) between treatment groups, but not in males. Amongst females, the difference was significant in women aged <44 years (fluoxetine, -18.4; maprotiline, -12.9; P=0.023) but not <greater than or equal to>44 years. Conclusions: Females in their reproductive period are more responsive to SSRI (fluoxetine) than norepinephrinergic tetracyclic antidepressant (maprotiline) treatment. Normal cyclical ovulation, and estrogen release may have a clinically relevant pharmacodynamic interaction with serotonergic antidepressants. (C) 2001 Elsevier Science B.V./ECNP. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 04:17:50